Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387608183> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4387608183 abstract "<div>AbstractPurpose:<p>Anal cancer is increasing in HIV<sup>+</sup> men who have sex with men (MSM). Treatment options for its precursor, high-grade anal intraepithelial neoplasia (HGAIN), are suboptimal. In this phase I to II dose-finding study, we assessed the safety and efficacy of the human papillomavirus type 16 (HPV16) synthetic long peptide vaccine (SLP-HPV-01) in HIV<sup>+</sup> MSM with HPV16-positive HGAIN.</p>Patients and Methods:<p>Four dosage schedules (1-5-10; 5-10-20; 10-20-40; and 40-40-40-40 μg) of SLP-HPV-01 were administered intradermally with a 3-week interval in 10 patients per dose level (DL). In each dose group, 5 patients also received 1 μg/kg pegylated IFNα-2b subcutaneously. Primary endpoints were safety and regression of HGAIN at 3, 6, and 12 months.</p>Results:<p>Eighty-one of 134 screened patients (60%) had HPV16-negative HGAIN lesions, leaving 53 eligible patients. Thirteen patients were excluded, leaving 40 men. The vaccine was well tolerated. One patient developed a generalized rash. The highest dosage level induced the strongest immune responses. There was no indication for stronger reactivity in the IFNα groups. Up to 18 months of follow-up, 8/38 intention-to-treat patients had a complete clinical and histologic response and one had a partial response (in total 9/38, 23.7%). At the highest dosage level, the clinical response was 4/10 (40%). Stronger immune responses were detected among clinical responders.</p>Conclusions:<p>The highest DL is safe, immunogenic, and associated with clinical responses to HPV16-induced lesions. However, as the majority of HGAIN is caused by the other HPV types, further studies should aim at pan-HPV vaccination to prevent or treat HGAIN.</p></div>" @default.
- W4387608183 created "2023-10-14" @default.
- W4387608183 creator A5015546063 @default.
- W4387608183 creator A5017577408 @default.
- W4387608183 creator A5020869847 @default.
- W4387608183 creator A5031418806 @default.
- W4387608183 creator A5035565968 @default.
- W4387608183 creator A5039123720 @default.
- W4387608183 creator A5041281028 @default.
- W4387608183 creator A5059027820 @default.
- W4387608183 creator A5060053979 @default.
- W4387608183 creator A5068299772 @default.
- W4387608183 creator A5069267169 @default.
- W4387608183 creator A5082771064 @default.
- W4387608183 creator A5092596791 @default.
- W4387608183 date "2023-10-13" @default.
- W4387608183 modified "2023-10-14" @default.
- W4387608183 title "Data from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men" @default.
- W4387608183 doi "https://doi.org/10.1158/1078-0432.c.6879414.v1" @default.
- W4387608183 hasPublicationYear "2023" @default.
- W4387608183 type Work @default.
- W4387608183 citedByCount "0" @default.
- W4387608183 crossrefType "posted-content" @default.
- W4387608183 hasAuthorship W4387608183A5015546063 @default.
- W4387608183 hasAuthorship W4387608183A5017577408 @default.
- W4387608183 hasAuthorship W4387608183A5020869847 @default.
- W4387608183 hasAuthorship W4387608183A5031418806 @default.
- W4387608183 hasAuthorship W4387608183A5035565968 @default.
- W4387608183 hasAuthorship W4387608183A5039123720 @default.
- W4387608183 hasAuthorship W4387608183A5041281028 @default.
- W4387608183 hasAuthorship W4387608183A5059027820 @default.
- W4387608183 hasAuthorship W4387608183A5060053979 @default.
- W4387608183 hasAuthorship W4387608183A5068299772 @default.
- W4387608183 hasAuthorship W4387608183A5069267169 @default.
- W4387608183 hasAuthorship W4387608183A5082771064 @default.
- W4387608183 hasAuthorship W4387608183A5092596791 @default.
- W4387608183 hasConcept C121608353 @default.
- W4387608183 hasConcept C126322002 @default.
- W4387608183 hasConcept C197934379 @default.
- W4387608183 hasConcept C203014093 @default.
- W4387608183 hasConcept C22070199 @default.
- W4387608183 hasConcept C2777343196 @default.
- W4387608183 hasConcept C2778220009 @default.
- W4387608183 hasConcept C2778570526 @default.
- W4387608183 hasConcept C2779840525 @default.
- W4387608183 hasConcept C2994532551 @default.
- W4387608183 hasConcept C44249647 @default.
- W4387608183 hasConcept C71924100 @default.
- W4387608183 hasConcept C90924648 @default.
- W4387608183 hasConceptScore W4387608183C121608353 @default.
- W4387608183 hasConceptScore W4387608183C126322002 @default.
- W4387608183 hasConceptScore W4387608183C197934379 @default.
- W4387608183 hasConceptScore W4387608183C203014093 @default.
- W4387608183 hasConceptScore W4387608183C22070199 @default.
- W4387608183 hasConceptScore W4387608183C2777343196 @default.
- W4387608183 hasConceptScore W4387608183C2778220009 @default.
- W4387608183 hasConceptScore W4387608183C2778570526 @default.
- W4387608183 hasConceptScore W4387608183C2779840525 @default.
- W4387608183 hasConceptScore W4387608183C2994532551 @default.
- W4387608183 hasConceptScore W4387608183C44249647 @default.
- W4387608183 hasConceptScore W4387608183C71924100 @default.
- W4387608183 hasConceptScore W4387608183C90924648 @default.
- W4387608183 hasLocation W43876081831 @default.
- W4387608183 hasOpenAccess W4387608183 @default.
- W4387608183 hasPrimaryLocation W43876081831 @default.
- W4387608183 hasRelatedWork W1976470591 @default.
- W4387608183 hasRelatedWork W2023345725 @default.
- W4387608183 hasRelatedWork W2487790087 @default.
- W4387608183 hasRelatedWork W2620636344 @default.
- W4387608183 hasRelatedWork W2762904155 @default.
- W4387608183 hasRelatedWork W3029528698 @default.
- W4387608183 hasRelatedWork W3147463158 @default.
- W4387608183 hasRelatedWork W4293231265 @default.
- W4387608183 hasRelatedWork W634189242 @default.
- W4387608183 hasRelatedWork W2560020715 @default.
- W4387608183 isParatext "false" @default.
- W4387608183 isRetracted "false" @default.
- W4387608183 workType "article" @default.